Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis by Yeo, Lorraine et al.
Extended report
Ann Rheum Dis 2011;70:2022–2028. doi:10.1136/ard.2011.153312 2022
Accepted 13 June 2011
Published Online First 
8 July 2011 
   ABSTRACT   
  Objectives      In rheumatoid arthritis (RA), a complex 
cytokine network drives chronic inﬂ  ammation and joint 
destruction. So far, few attempts have been made 
to identify the cellular sources of individual cytokines 
systematically. Therefore, the primary objective of 
this study was systematically to assess the cytokine 
messenger RNA expression proﬁ  les in the ﬁ  ve largest cell 
populations in the synovial ﬂ  uid and peripheral blood of 
RA patients. To reﬂ  ect the in vivo situation as closely as 
possible, the cells were neither cultured nor stimulated 
ex vivo.   
  Methods      Inﬂ  ammatory cells from 12 RA patients were 
sorted into CD4 and CD8 T cells, B cells, macrophages 
and neutrophils. mRNA expression for 41 cytokines was 
determined by real-time PCR using microﬂ  uidic cards. 
Receptor activator nuclear factor kappa B ligand (RANKL) 
(TNFSF11) expression by B cells was further conﬁ  rmed 
by ﬂ  ow cytometry and by immunoﬂ  uorescence staining of 
frozen sections of synovial tissue from patients with RA.   
  Results      The detection of cytokines characteristic for 
T cells and myeloid cells in the expected populations 
validated this methodology. Beyond the expected 
cytokine patterns, novel observations were made. Striking 
among these was the high expression of mRNA for 
RANKL in B cells from synovial ﬂ  uid. This observation was 
validated at the protein level in synovial tissue and ﬂ  uid.   
  Conclusions      RANKL, the key cytokine driving bone 
destruction by osteoclast activation, is produced by 
synovial B cells in RA. This observation is of importance 
for our understanding of the role of B cells in RA and their 
therapeutic  targeting.      
  Cytokines are recognised as important factors in 
the pathogenesis of rheumatoid arthritis (RA).  1     2   
In RA, the joint is inﬁ  ltrated by multiple inﬂ  am-
matory cell populations including T cells, B cells, 
macrophages and neutrophils, all of which contrib-
ute to the local cytokine network. Elucidating the 
cytokine network in RA represents an important 
challenge for furthering our understanding of dis-
ease   pathogenesis.  3    –    6   The ﬁ  rst step towards achiev-
ing this goal is to determine the cellular sources of 
the cytokines found in the rheumatoid joint. 
  Early studies of T-cell cytokine production in RA 
indicated that synovial T cells produce low levels 
of interleukin (IL) 2 and interferon gamma (IFNγ).  7    –    9   
More recently, IL-17-producing T cells have been 
reported in the RA synovium, where they are 
thought to promote inﬂ   ammation by activating 
local stromal cells.  10     11   Furthermore, RA synovial 
T cells have been shown to produce pro-inﬂ  am-
matory cytokines such as IL-6, tumour necro-
sis factor (TNF) alpha and TNF family members 
receptor activator nuclear factor kappa B ligand 
(RANKL) and lymphotoxin beta (LT-β).  12    –    15     B cells 
have proved to be a successful therapeutic target 
in RA, highlighting an important role for this cell 
type beyond their ability to produce antibody. 
RA synovial B cells can produce several cytokines 
including LT-β, which may be required for synovial 
ectopic lymphoid tissue formation and IL-6, which 
implicates a direct pro-inﬂ  ammatory role.  16     17   On 
the other hand, an IL-10-producing B-cell subset 
has been attributed with anti-inﬂ  ammatory prop-
erties.  18     19   So far, this population has not been 
described in the RA synovium. Macrophages are 
regarded as an important source of pro-inﬂ  amma-
tory cytokines found in the RA synovium including 
TNFα, IL-1 and IL-18.  13     20     21   Through expression 
of IL-7, IFNβ, IL-23, B-cell-activating factor of the 
TNF family (BAFF) and (a proliferation-inducing 
ligand) APRIL,   synovial macrophages are thought 
to play a role in synovial T-cell and B-cell differ-
entiation and survival.  22    –    26   Neutrophils represent 
the largest cell population in rheumatoid synovial 
ﬂ  uid and produce a range of cytokines including 
IL-1β, BAFF, APRIL and transforming growth fac-
tor beta (TGFβ) as well as the chemokines CCL3 
and CXCL8.  25     27    –    30   
  To date, no study has systematically determined 
cytokine production by synovial ﬂ  uid cell popu-
lations. The aim of the present study was there-
fore to identify the predominant cellular sources 
of cytokines in RA by comparing their expres-
sion across ﬁ  ve populations in RA synovial ﬂ  uid 
and peripheral blood. To achieve this we devel-
oped a new approach, which has the advantage 
of characterising cytokine proﬁ  les in cells directly 
ex vivo without culture or previous stimulation 
to reﬂ  ect the in vivo situation as closely as pos-
sible. Importantly, this strategy has enabled us to 
identify B cells inﬁ  ltrating the synovial ﬂ  uid and 
synovial tissue of RA patients as a major source of 
RANKL. This cytokine plays an important role in 
driving bone destruction in RA, and results from 
trials using a fully human monoclonal antibody 
speciﬁ  c for RANKL (denosumab) conﬁ  rm its role 
in erosive progression.  31   
  METHODS 
  Patients 
  Synovial ﬂ  uid and peripheral blood were obtained 
from 12 patients fulﬁ   lling the 1987 American 
College of Rheumatology criteria for RA.  32   All 
patients had disease of more than 3 months’ dura-
tion. Synovial ﬂ   uid was aspirated from joints 
under palpation or ultrasound guidance. Synovial 
tissue was taken by ultrasound-guided biopsy and 
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immediately frozen in liquid nitrogen. All patient material was 
obtained in agreement with the Helsinki declaration. Local 
ethical approval was obtained and   participants gave informed, 
written consent. Further clinical details are shown in   table 1  .     
    Isolation of cell populations 
  Synovial ﬂ  uid was incubated with 1000 U/ml endotoxin-free 
hyaluronidase (Hyalase; Wockhardt, UK)   at 37°C for 15 min to 
reduce viscosity. Mononuclear cells were isolated using density 
gradient centrifugation and stored at −80°C. Mononuclear cells 
were stained with mouse anti-human CD14-FITC (Immunotools, 
Friesoythe, Germany), CD19-PE (Immunotools), CD3-PE (eBio-
science), CD45RO-FITC (Biostat, Stockport, UK), CD4-APC 
(eBioscience) and CD8-PE Cy7 (eBioscience) on ice. Cells were 
sorted into CD14, CD19, CD3 CD45RO CD4 and CD3 CD45RO 
CD8 populations using a MoFlo cell sorter (Beckman Coulter, 
High Wycombe, UK). Neutrophils were isolated from synovial 
ﬂ  uid and peripheral blood by anti-CD15 microbeads (Miltenyi 
Biotec, Bisley, UK) and a magnetic-activated cell sorter. Isolated 
populations used had a minimum purity of 95%.   
    TaqMan low-density array analysis 
  TaqMan low-density real-time PCR arrays (Applied Biosystems, 
Paisley, UK) were designed to determine the expression of the 
following genes:   CCL2, CCL3, CCL4, CCL5, CCL11, CSF2, 
CSF3, CXCL12, EGF, FGF2, IFNA1, IFNB1, IFNG, IL1A, IL1B, 
IL2, IL4, IL5, IL6, IL7, IL8, IL10, IL11, IL12A, IL12B, IL13, 
IL15, IL17A, IL18, IL21, IL22, IL23A, IL27, LTB, MIF, TGFB1, 
TNFSF11  (RANKL)  ,TNFSF13, TNFSF13B, TNF, VEGFA, 
GAPDH and 18S  . RNA was extracted using a Nucleospin XS kit 
(Macherey-Nagel, Düren, Germany). A reaction mixture contain-
ing RNA, Quantitect-RT Master Mix (Qiagen) and QuantiTect 
Reverse Transcriptase (Qiagen, Crawley, UK) was added to a 
TaqMan low-density array microﬂ  uidic card. Reverse transcrip-
tion and real-time PCR was performed in a 7900HT Real-Time 
PCR System (Applied Biosystems). Relative gene expression 
(RQ) was expressed as 2  −ΔCt   where ΔCt represents the difference 
in Ct between 18S and the target gene. RQ values of 10  −5   or less 
were plotted on the x axis.   
  Immunoﬂ  uorescence staining of synovial tissue 
  Immunoﬂ   uorescence staining was performed on 5 μm tis-
sue sections using mouse anti-CD3 (UCHT-1, University of 
Birmingham), mouse anti-CD19 FITC (Dako) and rabbit anti-
RANKL (AbCam, Cambridge, UK). CD3 was developed with 
goat anti-mouse Cy5 (Southern Biotech, Alabama, USA), CD19 
was developed with goat anti-mouse FITC (Southern Biotech) 
and goat Alexa Fluor 488 anti-FITC (Molecular Probes, Paisley, 
UK), and RANKL was developed with donkey anti-rabbit 
Rhodamine (Jackson ImmunoResearch, Newmarket, UK). 
Concentration, and in the case of monoclonal antibodies, iso-
type-matched antibodies were used as controls. Sections were 
incubated at room temperature with primary antibody for 
1 h, washed in phosphate buffered saline (PBS), and incubated 
with secondary/tertiary antibodies for 30 min. PBS with 2% 
bovine serum albumin was used as a diluent. For nuclear coun-
terstaining, sections were immersed in Hoechst 33258 (Sigma, 
Gillingham, UK) at 20 μg/  ml for 2 min. A Zeiss confocal LSM 
510 microscope (Zeiss, Welwyn Garden City, UK) was used to 
capture images for processing using LSM Image Examiner soft-
ware (Zeiss).   
  Flow  cytometry 
  Mononuclear cells from synovial ﬂ  uid and peripheral blood were 
stained with mouse anti-RANKL-PE (eBioscience) and CD19-
Paciﬁ  c Blue (Biolegend, Cambridge, UK) or CD19-AlexaFluor 700 
(eBioscience). PBS with 0.5% bovine serum albumin was used 
as a diluent and washing buffer. Flow cytometry was performed 
using a Cyan ADP High Performance ﬂ  ow cytometer (Beckman 
Coulter). Data were analysed using SUMMIT and FlowJo.     
  RESULTS 
  We developed a novel technical approach to systematically 
determine messenger RNA expression of 41 cytokines in T cells, 
B cells, macrophages and neutrophils isolated from a single 
sample of synovial ﬂ  uid or peripheral blood from RA patients 
(see supplementary ﬁ  gure 1, available online only). In each of 
the isolated cell populations, the cytokine mRNA expression 
proﬁ  le was determined by real-time PCR. In a series of valida-
tion experiments we excluded bias due to sample preparation, 
normalisation and staining techniques (  ﬁ  gure 1  ). The results of 
these preliminary experiments conﬁ  rmed the robustness of the 
experimental approach taken and thus the validity of the results 
obtained in this study.     
The complete set of data showing a range of cytokine expres-
sion patterns in all ﬁ  ve cell populations in peripheral blood and 
synovial ﬂ  uid of RA patients is shown in the supplementary data 
(supplementary ﬁ  gure 1A–D, available online only). IL-4, IL-5, 
 Table  1     Details on patient clinical information   
 No   Gender  (M/F)   Age,  years 
 Disease 
duration, years 
 Rheumatoid 
factor 
 Anti-CCP 
antibody   DAS28  (ESR) 
 Current  disease-modifying 
antirheumatic drug/
glucocorticoid therapy 
1 M 79 1 Positive Positive 8.4 Nil
2 F 66 6 Negative Negative 4.3 Hydroxychloroquine
3 M 79 1 Positive Positive 4.4 Methotrexate, prednisolone
4 F 67 30 Positive Positive 7.1 Hydroxychloroquine, 
sulphasalazine
5 F 59 1 Positive Positive 5.0 Prednisolone
6 F 73 18 Positive Unknown 4.5 Methotrexate
7 F 58 6 Positive Positive 5.6 Prednisolone
8 F 75 40 Positive Positive 4.9 Methotrexate, sulphasalazine
9 M 41 6 Positive Positive 5.2 Methotrexate, adalimumab, 
prednisolone
10 F 55 5 Positive Positive 7.5 Methotrexate
11 M 52 2 Positive Negative 3.1 Nil
12 M 81 0.5 Positive Positive 6.2 Nil
      Anti-CCP, anti-cyclic citrullinated peptide; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate.   
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IL-13, IL-22, CCL11, CXCL12, CSF-3 and EGF mRNA was unde-
tectable in the majority of patients (data not shown). Positive 
controls (mRNA from T cells stimulated with magnetic beads 
coated with anti-CD3 and anti-CD28 antibody and a commer-
cially available blend of RNA from human cell lines representing 
different tissues (Stratagene, Stockport, UK)) were used to test 
whether these assays worked. With the exception of CSF-3 all 
of the cytokine mRNA species were detected. 
  A selection of cytokines expressed predominantly by lym-
phocytes in the synovial ﬂ  uid is shown in   ﬁ  gure 1  . In syn-
ovial ﬂ  uid T cells we detected the expression of IFNγ and IL-2 
mRNA. In the CD4 cell population we observed the expression 
of IL-17A mRNA suggesting the presence of T-helper (Th) type 
17 cells. We also found that IL-21, a cytokine reportedly pro-
duced by Th17 cells, was expressed in the CD4 T-cell popula-
tion.  33   The cytokines IL-12 and IL-23 are important regulators 
 Figure  1     Method validation. (A, B) B cells, monocytes, CD4 T cells and CD8 T cells were sorted based on their expression of CD19, CD14, CD4/
CD3/CD45R0 and CD8/CD3/CD45R0, respectively. (C) Neutrophils were isolated with CD15-coated magnetic beads. (D) All samples were re-analysed 
after the sort and samples with more than 5% contaminating cells were rejected. (E) To establish the cell number needed for the detection of cytokine 
gene expression, results for 1×10  3 ,  1×10 4   and 1×10  5   cells were directly compared in three independent experiments. There was a close correlation 
between the results yielded by the detection of 43 individual cytokine genes in 1×10  4   and 1×10  5   cells, conﬁ  rming that using a minimum cell number 
of 10  4   would be sufﬁ  cient for the sensitivity of the real-time PCR microﬂ  uidic card assay. Comparison of the results from 1×10  3   genes and 1×10  5  
cells showed a large degree of variation (data not shown). (F) Comparison of cytokine gene expression for mononuclear cells sorted on the basis 
of CD3 and CD4 expression compared with T cells sorted on the basis of CD4 expression and lack expression of the myeloid cell markers CD11c 
and CD11b. Under controlled experimental conditions, keeping the cells below 4°C, T cells sorted using anti-CD3 antibody did not have an altered 
expression proﬁ  le compared with T cells sorted using alternative markers, showing that under these conditions there is no induction of cytokine 
gene expression by the CD3 antibody (data representative of three independent experiments). (G) The cytokine mRNA expression was not altered 
by storing synovial ﬂ  uid mononuclear cells in freezing medium at −80°C compared with using freshly isolated cells (data representative of two 
independent experiments). PB, peripheral blood; SF, synovial ﬂ  uid; SFMC, synovial ﬂ  uid mononuclear cell.         
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of differentiation and survival of Th1 and Th17 cells, respec-
tively. Both cytokines are produced as heterodimers and have 
a common p40 subunit. The synovial ﬂ  uid B-cell population 
expressed high levels of IL-12p40 as well as IL-12p35 mRNA, 
suggesting that these cells may produce functionally active 
IL-12 (  ﬁ  gure 2  ). In agreement with previous publications, T 
cells expressed mRNA coding for the IL-23p19 subunit, which 
combines with the IL-12p40 subunit.  34   However, T cells did 
not express IL-12p40 mRNA, again leaving B cells as the only 
cell population among those analysed here expressing mRNA 
for both subunits required for the production of IL-23. High 
levels of mRNA-expression for CSF-2 (granulocyte mac-
rophage colony-stimulating factor) by CD4 T cells suggests a 
role for these cells in neutrophil survival. LT-β and IL-7 mRNA 
were both expressed in T cells and B cells, indicating a con-
tribution of both cell types to B-cell development and T-cell 
survival. 
  Intriguingly, RANKL (TNFSF11) mRNA was expressed pre-
dominantly by synovial ﬂ   uid B cells. Previous studies have 
reported the expression of RANKL by RA synovial ﬁ  broblasts, 
T cells and chondrocytes, but this is the ﬁ  rst report of RANKL 
expression in B cells in RA. We also found RANKL gene expres-
sion in CD4 T cells, but at a lower level compared with B cells. 
The expression of RANKL at the protein level is described in a 
later section of this paper and in   ﬁ  gure 5  .
      The data shown in   ﬁ  gure 3   describe cytokine mRNA expres-
sion found predominantly in the synovial ﬂ   uid myeloid cell 
populations investigated (neutrophils and macrophages). Our 
results indicate that macrophages constitute the major source 
of the pro-inﬂ  ammatory cytokine IL-1β, the Th1-differentiation 
factor IL-18 and IL-27, which is implicated in the differentia-
tion of several T-cell subsets. Macrophages were also found to 
be the main source of APRIL, CCL2, CCL3 and VEGF-α mRNA 
expression in RA synovial ﬂ  uid, conﬁ  rming their role in directing 
immune cell migration and differentiation as well as angiogen-
esis. Synovial ﬂ  uid neutrophils were found to express a range of 
cytokines very similar to macrophages. Particularly prominent 
was their expression of IFNα1, CXCL8 and BAFF mRNA.     
 Figure  2        Cytokine genes expressed predominantly in synovial ﬂ  uid 
lymphoid cells. Shown are the quantitative PCR results for the mRNA 
expression for a selection of the cytokines predominantly expressed in 
CD4 T cells, CD8 T cells or in CD19 B cells (B). Statistical signiﬁ  cance 
was assessed by the Kruskal–Wallis test. *p<0.05, **p<0.001, 
***p<0.0001.    
 Figure  3        Cytokine genes expressed predominantly in synovial ﬂ  uid 
macrophages or neutrophils. Shown are the quantitative PCR results for 
the mRNA expression for a selection of the cytokines (N) predominantly 
expressed in either CD14 monocytes (M) or CD15 neutrophils. 
Statistical signiﬁ  cance was assessed by the Kruskal–Wallis test. 
**p<0.001,  ***p<0.0001.    
annrheumdis153312.indd   2025 annrheumdis153312.indd   2025 9/23/2011   11:07:16 AM 9/23/2011   11:07:16 AMExtended report
Ann Rheum Dis 2011;70:2022–2028. doi:10.1136/ard.2011.153312 2026
Cytokines highly expressed in both lymphocyte and myeloid 
cell populations are shown in   ﬁ  gure 4  . IL-1α was expressed at 
similar levels by macrophages, B cells and neutrophils in RA 
synovial ﬂ  uid. B cells and macrophages comprised the major 
sources of IL-6, while T cells and macrophages were the pri-
mary producers of IL-10 mRNA. T-cell, B-cell and macrophage 
populations all expressed IL-15. TNFα, TGFβ1, MIF and CCL4 
mRNA were highly expressed by all lymphocyte and myeloid 
cell populations investigated.
      Comparison of cytokine proﬁ  les in all ﬁ  ve cell populations in 
synovial ﬂ  uid and peripheral blood showed that a wide range of 
cytokines was expressed at a higher level in synovial ﬂ  uid (see 
supplementary ﬁ  gure 3, available online only). In the T-cell, B-cell 
and macrophage populations the majority of cytokines detected 
were over-expressed at the site of inﬂ  ammation, in the synovial 
ﬂ  uid. Interestingly, this was not the case for neutrophils. 
  Several novel observations of cytokine gene expression have 
been made in the context of this study. Because of its clinical 
relevance to the progression of joint destruction in RA patients, 
the observation of RANKL mRNA expression in synovial ﬂ  uid 
B cells was extended to the protein level. First, the mRNA gene 
expression data were normalised to cell number (  ﬁ  gure 5A  ) in 
order to exclude potential bias arising from normalisation to 18S 
rRNA. Conﬁ  rming our original observation, PCR data norma-
lised to cell number identiﬁ  ed synovial ﬂ  uid CD19 B cells as the 
dominant producers of RANKL mRNA, while a smaller propor-
tion of CD4 T cells also showed RANKL mRNA expression. The 
surface expression of RANKL on synovial ﬂ  uid mononuclear 
cells was determined by co-labelling for CD19 and RANKL and 
ﬂ  ow cytometric analysis. While only a very small proportion of 
B cells expressed RANKL in the peripheral blood of RA patients, 
a signiﬁ  cantly higher proportion of B cells from synovial ﬂ  uid 
samples expressed RANKL on their surface (  ﬁ  gure 5  ). 
  A large proportion of the B cells in the inﬂ  amed joint are loc-
alised in the synovial tissue, while they are a relatively small 
population among the synovial ﬂ  uid cells (see supplementary 
ﬁ  gure 2, available online only). To test whether synovial tis-
sue B cells produced RANKL, frozen sections of synovial tissue 
from biopsies taken from RA patients with active disease were 
stained with antibodies to RANKL and CD19. Distinct RANKL 
expression was identiﬁ  ed in CD19+ B cells in the inﬂ  amed syn-
ovium (  ﬁ  gure 5  ). This observation was mainly made in B cells 
dispersed throughout the sublining and more rarely in lymphoid 
aggregates.   
  DISCUSSION 
  In this study a novel strategy was used to compare cytokine 
expression in the ﬁ  ve dominant immune cell populations in the 
synovial ﬂ  uid and peripheral blood of RA patients without ex 
vivo stimulation. We also detected the expression of several 
chemokines and growth factors that contribute to cell recruit-
ment and survival in the RA joint.  35   While many cytokines were 
found in the populations we would have predicted based on the 
existing literature, we also made several unexpected ﬁ  ndings. 
Notably, we observed that synovial ﬂ  uid B cells express high 
levels of pro-inﬂ  ammatory cytokines. The B-cell population was 
the only synovial ﬂ  uid population that expressed both IL-12p35 
and IL-12p40, the two subunits that are required for the produc-
tion of functional IL-12. This observation is supported by previ-
ous reports of IL-12 production by B cells.  36   Synovial ﬂ  uid B cells 
also expressed IL-23p19, the subunit that heterodimerises with 
IL-12p40 to form IL-23, indicating that synovial ﬂ  uid B cells also 
have the capacity to produce functional IL-23. We found that 
IL-23p19 was expressed predominantly by synovial ﬂ  uid T cells, 
in agreement with the original publication that reported high 
levels of IL-23p19 in polarised Th1 cells.  34   However, our obser-
vation that synovial ﬂ  uid CD4 and CD8 T cells do not express 
IL-12p40 mRNA raises the question of whether synovial ﬂ  uid 
T cells express a yet undescribed alternative binding partner for 
IL-23p19. A discrepancy between the level of IL-23p19 mRNA 
expression and functional expression of IL-23 at the protein level 
has also been described in RA synovial tissue and ﬁ  broblast-like 
synoviocytes.  37   
  While it is thought that differentiation towards plasma cells 
and the production of rheumatoid factor and anti-citrullinated 
protein antibodies contribute to disease, B cells are likely to play 
further roles. Antigen presentation by B cells is likely to play 
a role in the local activation of T cells thus indirectly increas-
ing T-cell cytokine production, but little is known about direct 
cytokine production by B cells in the RA synovium.  38   An anti-
inﬂ  ammatory role has been proposed for a subset of B cells that 
can produce IL-10.  18     19     39     40   These cells have been observed in 
 Figure  4     Cytokines expressed in both synovial ﬂ  uid myeloid and 
lymphoid cell populations. Shown are the quantitative PCR results for 
the mRNA expression for a selection of the cytokines expressed in at 
least one of the lymphoid cell populations: CD4 T cells, CD8 T cells or 
in CD19 B cells as well as either CD14 monocytes or CD15 neutrophils. 
Statistical signiﬁ  cance was assessed by the Kruskal–Wallis test. 
*p<0.05,  **p<0.001,  ***p<0.0001.     
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peripheral blood of patients with autoimmune diseases includ-
ing RA, but have not been reported in the rheumatoid joint 
so far. The mRNA cytokine proﬁ   le of synovial ﬂ   uid B cells 
detected in this study does not support a major contribution of 
B cells to IL-10 production, but rather supports a generally pro-
  inﬂ  ammatory role for this cell type in the synovial ﬂ  uid. 
  This is the ﬁ   rst study to report that B cells contribute to 
RANKL production in the inﬂ  amed rheumatoid joint. Previous 
studies have reported the expression of RANKL by RA synovial 
ﬁ  broblasts, T cells and chondrocytes, and that levels of soluble 
RANKL are elevated in synovial ﬂ  uid compared with the serum 
of RA patients.  41    –    44   RANKL is known to be required for osteoclast 
development and plays a key role in mediating bone erosion.  45   
Of relevance to our observation that synovial B cells express this 
cytokine, RANKL has been identiﬁ  ed as part of a distinct expres-
sion proﬁ  le that deﬁ  nes a subset of memory B cells that normally 
reside in epithelial niches.  46   Furthermore, RANKL has been 
detected in B cells in the gingival tissue of patients with peri-
odontal disease and in plasma cells in osteolytic myeloma bone 
disease, in which it is associated with bone degradation.  47     48   
  RANKL-deﬁ  cient mice have altered B and T cell populations 
and lack lymph nodes indicating that RANKL plays a role in 
lymphocyte development and lymph node organogenesis.  45   
The development of ectopic lymphoid structures and lymphoid 
neogenesis is a poorly   understood feature of many chronic 
inﬂ  ammatory diseases including RA.  49   It will be intriguing to 
investigate how the production of RANKL by B cells at sites of 
chronic inﬂ  ammation contributes to the development of these 
lymphoid aggregates. 
  Data from the REFLEX trial revealed that the B-cell targeting 
therapy rituximab, in combination with methotrexate, caused 
signiﬁ  cant reduction in joint damage progression compared with 
methotrexate alone.  50   Together with our observation of RANKL 
production by B cells in the synovial tissue and ﬂ   uid of RA 
 Figure  5        Expression of receptor activator nuclear factor kappa B ligand (RANKL) in B cells inﬁ  ltrating the rheumatoid synovial tissue and ﬂ  uid. 
(A) Quantitative PCR data for detection of RANKL in sorted peripheral blood (PB) and synovial ﬂ  uid (SF) CD4 and CD8 T cells, CD19 B cells and 
CD14 monocytes/macrophages. Data normalised to the exact number of cells sorted. (B) Flow cytometric detection of RANKL. Peripheral blood and 
synovial ﬂ  uid mononuclear cells were co-labelled with anti-CD19 and either isotype matched control or anti-RANKL antibody. Staining representative 
of samples from eight patients with rheumatoid arthritis (RA). (C) Percentage of RANKL  +   cells among the CD19 B cells of RA patients as detected by 
ﬂ  ow cytometry. (D) Detection of RANKL  +   B cells in synovial tissue. Synovial tissue was stained for CD19 (green), and RANKL (red) and viewed at a 
ﬁ  nal magniﬁ  cation of ×400. Representative sections from ﬁ  ve RA patients were investigated.       
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patients, this suggests that depletion of RANKL-expressing B cells 
may contribute to the inhibition of bone erosion by rituximab.  50                 
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